Evidence map›Paper›PMID 41030957›Full record

ArticlebioRxiv : the preprint server for biology2025

Generation of

Rachel Coneys, Alexander J Cammack, Remya R Nair, David Thompson, Jonas Mechtersheimer, Mireia Carcolé, Yashica Gupta, Gabriel E Rech, Michael Flower, Niamh O'Brien and 9 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Rachel ConeysUK Dementia Research Institute at UCL, London, UK.
Alexander J CammackUK Dementia Research Institute at UCL, London, UK.
Remya R NairMammalian Genetics Unit, MRC Harwell Institute, Oxfordshire, UK.
David ThompsonMammalian Genetics Unit, MRC Harwell Institute, Oxfordshire, UK.
Jonas MechtersheimerUK Dementia Research Institute at UCL, London, UK.
Mireia CarcoléUK Dementia Research Institute at UCL, London, UK.
Yashica GuptaUK Dementia Research Institute at UCL, London, UK.
Gabriel E RechThe Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.
Michael FlowerUK Dementia Research Institute at UCL, London, UK.
Niamh O'BrienUK Dementia Research Institute at King's College London, UK.
Marc-David RueppUK Dementia Research Institute at King's College London, UK.
Sarah MizielinskaUK Dementia Research Institute at King's College London, UK.
Fiona DucotterdAlzheimer's Research UK UCL Drug Discovery Institute, London, UK.
Sarah J TabriziUK Dementia Research Institute at UCL, London, UK.
Elizabeth M C FisherDepartment of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, UK.ORCID 0000-0003-2850-9936
Thomas J CunninghamMammalian Genetics Unit, MRC Harwell Institute, Oxfordshire, UK.
Michael WardNeurogenetics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0002-5296-8051
William C SkarnesThe Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.
Adrian M IsaacsUK Dementia Research Institute at UCL, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Induced pluripotent stem cell (iPSC) models are powerful tools for neurodegenerative disease modelling, as they allow mechanistic studies in a human genetic environment and they can be differentiated into a range of neuronal and non-neuronal cells. However, these models come with inherent challenges due to line-to-line and clonal variability. To combat this issue, the iPSC Neurodegenerative Disease Initiative (iNDI) has generated an iPSC repository using a single clonal reference line, KOLF2.1J, into which disease-causing mutations and revertants are introduced via gene editing. Here we describe the generation and validation of lines carrying the most common causative mutation for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), a repeat expansion in the

Identifiers

PMID41030957
PMCPMC12478360

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.